MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 0.7% Higher – Here’s What Happened

Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) traded up 0.7% during trading on Tuesday . The company traded as high as $1.5861 and last traded at $1.50. 1,222,219 shares changed hands during trading, an increase of 4% from the average session volume of 1,180,232 shares. The stock had previously closed at $1.49.

MAIA Biotechnology Stock Performance

The business’s 50 day moving average is $1.95 and its two-hundred day moving average is $1.58. The firm has a market capitalization of $60.70 million, a PE ratio of -2.15 and a beta of -0.04.

Insider Buying and Selling at MAIA Biotechnology

In other news, Director Steven M. Chaouki bought 40,849 shares of MAIA Biotechnology stock in a transaction that occurred on Monday, December 22nd. The shares were acquired at an average price of $1.22 per share, with a total value of $49,835.78. Following the completion of the purchase, the director directly owned 151,873 shares in the company, valued at $185,285.06. The trade was a 36.79% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ngar Yee Louie purchased 81,699 shares of the stock in a transaction on Monday, December 22nd. The shares were purchased at an average price of $1.22 per share, for a total transaction of $99,672.78. Following the transaction, the director directly owned 1,248,888 shares of the company’s stock, valued at approximately $1,523,643.36. This represents a 7.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 179,737 shares of company stock worth $219,279 over the last three months. 32.32% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Centric Wealth Management grew its position in MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after acquiring an additional 505,150 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology during the fourth quarter valued at approximately $120,000. Geode Capital Management LLC boosted its stake in shares of MAIA Biotechnology by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock valued at $454,000 after purchasing an additional 25,684 shares during the period. Ritholtz Wealth Management bought a new position in shares of MAIA Biotechnology in the fourth quarter worth approximately $35,000. Finally, Marshall Wace LLP bought a new position in shares of MAIA Biotechnology in the second quarter worth approximately $29,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.